Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | SYK | P43405 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | FOS | P01100 | 1/20 | 0.57 |
| ▸ | JUN | P05412 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.53 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508872 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SYKMAPTLMNASMN1; SMN2 | |
| SCHEMBL26930605 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SYKMAPTLMNASMN1; SMN2 | |
| SCHEMBL26930607 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SYKMAPTLMNASMN1; SMN2 | |
| SCHEMBL22860492 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SYKMAPTLMNASMN1; SMN2 | |
| SCHEMBL574167 | 0.95 | ALDH1A1 (0.60) | ALDH1A1SYKMAPTLMNASMN1; SMN2 | |
| SCHEMBL22860692 | 0.95 | ALDH1A1 (0.60) | ALDH1A1SYKMAPTLMNASMN1; SMN2 | |
| SCHEMBL30498501 | 0.95 | ALDH1A1 (0.60) | ALDH1A1SYKMAPTLMNASMN1; SMN2 | |
| SCHEMBL4715162 | 0.94 | ALDH1A1 (0.61) | ALDH1A1SYKMAPTLMNASMN1; SMN2 | |
| SCHEMBL5266863 | 0.94 | ALDH1A1 (0.61) | ALDH1A1SYKMAPTLMNASMN1; SMN2 | |
| SCHEMBL4157935 | 0.92 | ALDH1A1 (0.57) | ALDH1A1SYKMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137393-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASES 2, 4, AND 6 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2023239165-A1 | PHENYLSULFONAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11713309-B2 | Solid forms of Cerdulatinib | ALEXION PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713309-B2 | Solid forms of Cerdulatinib | ALEXION PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11339145-B2 | Synthesis of cerdulatinib | ALEXION PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210147392-A1 | SYNTHESIS OF CERDULATINIB | ALEXION PHARMACEUTICALS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210130330-A1 | SOLID FORMS OF CERDULATINIB | ALEXION PHARMACEUTICALS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10865198-B2 | Solid forms of cerdulatinib | ALEXION PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2006003378-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130330-A1 | SOLID FORMS OF CERDULATINIB | CLK1, CLK2, DCLK1 | ALDH1A1 4487/4885SYK 1096/4885MAPT 1238/4885 |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | ALDH1A1 1162/4885SYK 2342/4885MAPT 2259/4885 |
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | ALDH1A1 1779/4885SYK 369/4885MAPT 3541/4885 |
| US-20210147392-A1 | SYNTHESIS OF CERDULATINIB | JAK2, DCK, CERS2 | ALDH1A1 2168/4885SYK 644/4885MAPT 3748/4885 |
| US-11713309-B2 | Solid forms of Cerdulatinib | CLK1, CLK2, DCLK1 | ALDH1A1 4487/4885SYK 1096/4885MAPT 1238/4885 |
| US-10865198-B2 | Solid forms of cerdulatinib | CLK1, CLK2, DCLK1 | ALDH1A1 4487/4885SYK 1096/4885MAPT 1238/4885 |
| US-11339145-B2 | Synthesis of cerdulatinib | JAK2, DCK, CERS2 | ALDH1A1 2168/4885SYK 644/4885MAPT 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.